Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity & Safety of GSK1562902A in Adults Over 60
NCT00397215Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Primary completion
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of Adjupanrix in Influenza A H5N1 (H5N1) (4 arms), sponsored by GSK. Primary endpoints: Titers for Serum Hemagglutination Inhibition (HI) Antibodies at Month 24, Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies at Month 24 and 4 more. Started Nov 2006; status: completed.
02
Drugs
Adjupanrix
03
Conditions
Influenza A H5N1 (H5N1)
Beyond the preview
Go deeper on NCT00397215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397215.